Latest News
Starpharma receives $7.7M R&D tax incentive refund (ASX Announcement)
Jan 20th, 2022
Starpharma today announced it has received a $7.7M research and development (R&D) tax incentive refund related to the company’s Australian and international R&D expenses from the 2021 financial year. The tax refund is for eligible R&D activities across Starpharma’s portfolio, including the company’s DEP® oncology products and VIRALEZE™ antiviral nasal spray.
Read More
Shareholder Newsletter December 2021
Dec 16th, 2021
The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – December 2021 is now available to view online.
Read More
VIRALEZE™ antiviral nasal spray registered in Saudi Arabia (ASX Announcement)
Dec 14th, 2021
Starpharma today announced that VIRALEZE™ antiviral nasal spray has been registered for sale in Saudi Arabia. This is the first registration for VIRALEZE™ in the Middle East and registration in Saudi Arabia is an important step for other countries in the region.
Read More
VIRALEZE™ successfully launched in Vietnam (ASX Announcement)
Dec 13th, 2021
Starpharma today announced that since signing the commercial arrangement for VIRALEZE™ antiviral nasal spray in Vietnam, the company has received orders in excess of A$2 million, since late October. Some orders have already been delivered with further product expected to be delivered in the New Year. VIRALEZE™ successfully launched in Vietnam last week, with the formal launch events attended by clinicians, healthcare professionals, politicians, and media representatives from over 30 news channels.
Read More
